Want to join the conversation?
$AVGO, which competes with $ADI and $FNSR, said that 1Q16 GM from continuing operations was 61%, which was at the midpoint of the guidance range. R&D expense was $238MM and SG&A expense was $68MM resulting in total OpEx of $306MM, $8MM below guidance. Percentage-wise, total OpEx was 17% of revenue.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.